Skip to content
DataLookout
Menu

ADAPT-EARLYNCT06909214

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

StatusRecruiting
PhasePhase 4
Sponsorargenx
Primary completion

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 6 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Enrollment increased: 30 → 35 participants
    • Study completion pushed from May 2027 to Dec 2027
    • Primary completion date changed from estimate of Aug 2026 to Jul 8, 2026
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised at 1 of 18 sites
  2. Minor Site details revised at 1 of 18 sitesv10
  3. Minor Study sites: 17 to 18v9
  4. Minor Study sites: 16 to 17v8
  5. Minor Study sites: 15 to 16v7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Study sites: 12 to 15v6
  2. Minor Study sites: 4 to 12v5
  3. Minor Study sites: 3 to 4v4
  4. Minor Study sites: 1 to 3v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2025 to Apr 17, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of participants who reach MSE of MG at any time within the first 16 weeks of stage 1 treatment with efgartigimod PH20 SC
Timeframe: up to 16 weeks

Secondary (4)

Changes from baseline in MG-ADL total scores over time
Changes from baseline in MG-QOL-15r total scores over time
Proportion of participants who are administered systemic corticosteroid therapy as background add-on therapy throughout the study
Incidence of adverse events, serious adverse events and adverse events leading to study drug discontinuation

Arms and interventions

Efgartigimod PH20 SCExperimental

Participants receiving efgartigimod PH20 SC

Biologicals: Efgartigimod PH20 SC

Sites

18 sites in 1 country